ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 106 filers reported holding ASCENDIS PHARMA A/S in Q4 2018. The put-call ratio across all filers is 0.16 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $478 | +142.6% | 5,364 | +231.7% | 0.00% | – |
| Q4 2022 | $197 | -99.7% | 1,617 | +274.3% | 0.00% | – |
| Q3 2021 | $58,000 | +3.6% | 432 | 0.0% | 0.00% | – |
| Q2 2021 | $56,000 | -78.1% | 432 | -78.3% | 0.00% | – |
| Q1 2021 | $256,000 | -63.9% | 1,994 | -53.2% | 0.00% | -100.0% |
| Q4 2020 | $710,000 | +296.6% | 4,258 | +266.1% | 0.00% | – |
| Q3 2020 | $179,000 | -39.5% | 1,163 | -42.1% | 0.00% | – |
| Q2 2020 | $296,000 | -66.9% | 2,007 | -74.7% | 0.00% | -100.0% |
| Q1 2020 | $893,000 | +75.8% | 7,934 | +50.2% | 0.00% | +100.0% |
| Q3 2019 | $508,000 | -6.8% | 5,284 | +11.6% | 0.00% | 0.0% |
| Q2 2019 | $545,000 | -42.0% | 4,733 | -68.4% | 0.00% | -66.7% |
| Q4 2018 | $939,000 | +394.2% | 14,993 | +423.5% | 0.00% | +200.0% |
| Q2 2018 | $190,000 | – | 2,864 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |